Published in J Virol on December 01, 2004
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol (2006) 2.76
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 2.33
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One (2009) 1.72
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med (2008) 1.67
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
The structural immunology of antibody protection against West Nile virus. Immunol Rev (2008) 1.63
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One (2011) 1.36
Crystal structure of the Japanese encephalitis virus envelope protein. J Virol (2011) 1.26
Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol (2012) 1.25
Is there a risk of yellow fever virus transmission in South Asian countries with hyperendemic dengue? Biomed Res Int (2013) 1.22
Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis (2012) 1.22
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol (2012) 1.12
Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res (2008) 1.09
Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile disease. Int J Environ Res Public Health (2013) 1.08
In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein. J Virol (2010) 1.07
Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol (2012) 1.07
Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol (2008) 1.06
Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators. Mediators Inflamm (2015) 1.05
A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology (2014) 1.03
In vitro and in vivo studies identify important features of dengue virus pr-E protein interactions. PLoS Pathog (2010) 1.02
Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology (2012) 1.01
Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines. Clin Vaccine Immunol (2007) 1.01
Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol (2007) 1.01
Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol (2008) 1.01
Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections. J Clin Microbiol (2005) 1.01
Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies. Clin Vaccine Immunol (2009) 0.99
Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis (2007) 0.99
Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 0.98
A novel system for rapid and cost-effective production of detection and diagnostic reagents of West Nile virus in plants. J Biomed Biotechnol (2011) 0.98
Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog (2013) 0.97
Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol (2010) 0.95
Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis (2012) 0.95
The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog (2013) 0.94
Virus-like particles production in green plants. Methods (2006) 0.94
Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis (2012) 0.93
Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis (2014) 0.93
Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J (2012) 0.92
Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies. Clin Vaccine Immunol (2010) 0.92
Zika Virus: Immunity and Vaccine Development. Cell (2016) 0.89
Structure of the St. Louis encephalitis virus postfusion envelope trimer. J Virol (2012) 0.88
First international external quality assessment study on molecular and serological methods for yellow fever diagnosis. PLoS One (2012) 0.87
Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol (2012) 0.87
Comprehensive Mapping Antigenic Epitopes of NS1 Protein of Japanese Encephalitis Virus with Monoclonal Antibodies. PLoS One (2013) 0.87
The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol (2013) 0.86
A toggle switch controls the low pH-triggered rearrangement and maturation of the dengue virus envelope proteins. Nat Commun (2014) 0.86
Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections. PLoS Negl Trop Dis (2015) 0.86
Removal of species constraints in antibody detection. Clin Vaccine Immunol (2009) 0.84
Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3). PLoS One (2009) 0.84
Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. J Virol (2015) 0.84
A plant-produced antigen elicits potent immune responses against West Nile virus in mice. Biomed Res Int (2014) 0.83
A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies. Virol J (2013) 0.83
Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro. PLoS Curr (2016) 0.82
Genetic and phenotypic characterization of sylvatic dengue virus type 4 strains. Virology (2011) 0.82
Bioinformatics in new generation flavivirus vaccines. J Biomed Biotechnol (2010) 0.81
The relevance of dengue virus genotypes surveillance at country level before vaccine approval. Hum Vaccin Immunother (2014) 0.80
Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus. Biologics (2013) 0.79
Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISA. PLoS Negl Trop Dis (2013) 0.79
Development of a high-throughput colorimetric Zika virus infection assay. Med Microbiol Immunol (2017) 0.78
The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. Microbiol Mol Biol Rev (2017) 0.78
Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III. PLoS Negl Trop Dis (2015) 0.78
BST2/tetherin inhibition of alphavirus exit. Viruses (2015) 0.77
A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance. Sci Rep (2016) 0.77
Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies. BMC Res Notes (2012) 0.77
Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine. PLoS One (2014) 0.77
Transposon mutagenesis of the Zika virus genome highlights regions essential for RNA replication and restricted for immune evasion. J Virol (2017) 0.76
Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine (2017) 0.76
An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2. PLoS Negl Trop Dis (2015) 0.76
Measuring Haitian children's exposure to chikungunya, dengue and malaria. Bull World Health Organ (2016) 0.76
Zika virus infection of cellular components of the blood-retinal barriers: implications for viral associated congenital ocular disease. J Neuroinflammation (2017) 0.75
Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III. PLoS One (2015) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions. Clin Vaccine Immunol (2015) 0.75
Epitope Identification and Application for Diagnosis of Duck Tembusu Virus Infections in Ducks. Viruses (2016) 0.75
The Molecular Epidemiology and Evolution of Murray Valley Encephalitis Virus: Recent Emergence of Distinct Sub-lineages of the Dominant Genotype 1. PLoS Negl Trop Dis (2015) 0.75
In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate. Clin Exp Vaccine Res (2016) 0.75
Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein. PLoS One (2015) 0.75
Identification of a New Broadly Cross-reactive Epitope within Domain III of the Duck Tembusu Virus E Protein. Sci Rep (2016) 0.75
Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection. J Virol (2016) 0.75
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Front Microbiol (2017) 0.75
Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies. Virology (2017) 0.75
A novel mechanism of antibody-mediated enhancement of flavivirus infection. PLoS Pathog (2017) 0.75
Identification of diagnostic peptide regions that distinguish Zika virus from related mosquito-borne Flaviviruses. PLoS One (2017) 0.75
Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement. PLoS Negl Trop Dis (2017) 0.75
Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci Rep (2017) 0.75
SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis (1997) 57.27
Pathogenesis of dengue: challenges to molecular biology. Science (1988) 14.73
The atomic structure of protein-protein recognition sites. J Mol Biol (1999) 12.63
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol (2002) 10.92
Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol (2002) 9.74
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Phylogeny of the genus Flavivirus. J Virol (1998) 8.87
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science (1985) 8.54
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06
Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol (2001) 4.27
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol (1995) 3.67
Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol (2001) 3.58
Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A (1996) 3.53
Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis (1989) 3.53
The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc Natl Acad Sci U S A (1999) 3.06
Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol (1999) 2.87
Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol (1989) 2.59
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 2.56
A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Nat Struct Biol (1999) 2.47
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg (1982) 2.41
Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A (1994) 2.18
Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis (2002) 2.17
Dengue and other emerging flaviviruses. J Infect (2001) 2.05
Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg (1985) 2.04
Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol (2003) 1.88
X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat Struct Biol (2003) 1.81
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine (2001) 1.79
Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J Virol (1993) 1.72
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg (2002) 1.70
A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen. J Virol Methods (2001) 1.55
Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology (2003) 1.50
A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J Virol (2000) 1.46
Protection against West Nile virus induced by a previous injection with dengue virus. Am J Epidemiol (1971) 1.42
Molecular basis of crossreactivity and the limits of antibody-antigen complementarity. Nature (1993) 1.38
Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology (1992) 1.30
Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol (1992) 1.19
Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). Arch Virol (1989) 1.16
Recent advancement in flavivirus vaccine development. Expert Rev Vaccines (2004) 1.10
Questions on viral population biology to complete dengue puzzle. Trends Microbiol (2003) 1.04
Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol (2003) 1.04
Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63(,). Biochemistry (2000) 1.03
The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites. J Mol Biol (2001) 0.97
Structural basis for the binding of an anti-cytochrome c antibody to its antigen: crystal structures of FabE8-cytochrome c complex to 1.8 A resolution and FabE8 to 2.26 A resolution. J Mol Biol (1998) 0.96
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Development of real-time reverse transcriptase PCR assays to detect and serotype dengue viruses. J Clin Microbiol (2006) 2.45
Biological transmission of arboviruses: reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends. Clin Microbiol Rev (2005) 1.91
Laboratory diagnosis of dengue virus infection: current and future perspectives in clinical diagnosis and public health. J Microbiol Immunol Infect (2005) 1.81
Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One (2009) 1.72
Development of multiplex real-time reverse transcriptase PCR assays for detecting eight medically important flaviviruses in mosquitoes. J Clin Microbiol (2006) 1.53
Complete genome characterization of Rocio virus (Flavivirus: Flaviviridae), a Brazilian flavivirus isolated from a fatal case of encephalitis during an epidemic in Sao Paulo state. J Gen Virol (2007) 1.25
Experimental infection of cats and dogs with West Nile virus. Emerg Infect Dis (2004) 1.25
Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J Gen Virol (2009) 1.22
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine (2009) 1.11
Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology (2005) 1.10
A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J Gen Virol (2007) 1.07
Strategically examining the full-genome of dengue virus type 3 in clinical isolates reveals its mutation spectra. Virol J (2005) 1.06
Mutation analysis of the fusion domain region of St. Louis encephalitis virus envelope protein. Virology (2006) 1.05
Comparative analysis of full genomic sequences among different genotypes of dengue virus type 3. Virol J (2008) 1.04
Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol (2007) 1.01
DNA vaccination of American robins (Turdus migratorius) against West Nile virus. Vector Borne Zoonotic Dis (2010) 1.01
Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol (2008) 1.01
Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections. J Clin Microbiol (2005) 1.01
gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection. FEMS Immunol Med Microbiol (2010) 1.00
Characterization of Sepik and Entebbe bat viruses closely related to yellow fever virus. Am J Trop Med Hyg (2006) 0.98
Noninfectious recombinant antigen for detection of St. Louis encephalitis virus-specific antibodies in serum by enzyme-linked immunosorbent assay. J Clin Microbiol (2004) 0.98
Identification of new flaviviruses in the Kokobera virus complex. J Gen Virol (2005) 0.95
Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine. PLoS Negl Trop Dis (2012) 0.95
Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis (2012) 0.93
Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J (2012) 0.92
DNA vaccination of the American crow (Corvus brachyrhynchos) provides partial protection against lethal challenge with West Nile virus. Avian Dis (2007) 0.90
Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr (2009) 0.89
Efficacy of three vaccines in protecting Western Scrub-Jays (Aphelocoma californica) from experimental infection with West Nile virus: implications for vaccination of Island Scrub-Jays (Aphelocoma insularis). Vector Borne Zoonotic Dis (2011) 0.89
Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol (2012) 0.87
Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein. Virology (2010) 0.85
Comparison of a commercial dengue IgM capture ELISA with dengue antigen focus reduction microneutralization test and the Centers for Disease Control dengue IgM capture-ELISA. J Virol Methods (2013) 0.83
A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Virology (2012) 0.81
Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol (2004) 0.80
A comparison of concentration methods applied to non-infectious flavivirus recombinant antigens for use in diagnostic serological assays. J Virol Methods (2007) 0.80
Effect of West Nile virus DNA-plasmid vaccination on response to live virus challenge in red-tailed hawks (Buteo jamaicensis). Am J Vet Res (2011) 0.78
Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein. J Gen Virol (2012) 0.78
First detection of the Africa/Caribbean/Latin American subtype of Culex flavivirus in Asian country, Taiwan. Comp Immunol Microbiol Infect Dis (2013) 0.77
Microcarrier culture of COS-1 cells producing Japanese encephalitis and dengue virus serotype 4 recombinant virus-like particles. J Virol Methods (2008) 0.75